Peer-reviewed publications

1. Arcangeli S, Tozzi A, Tantucci M, Spaccatini C, de Iure A, Costa C, Di Filippo M, **Picconi B**, Giampa C, Fusco FR, Amoroso S, Calabresi P (2013) Ischemic-LTP in striatal spiny neurons of both direct and indirect pathway requires the activation of D1-like receptors and NO/soluble guanylate cyclase/cGMP transmission. J Cereb Blood Flow Metab 33:278-286. **(IF = 5.00)**
2. Calabresi P, Di Filippo M, Gallina A, Wang Y, Stankowski JN, **Picconi B**, Dawson VL, Dawson TM (2013) New synaptic and molecular targets for neuroprotection in Parkinson's disease. Mov Disord 28:51-60. **(IF = 4.505)**
3. Tozzi A, de Iure A, Di Filippo M, Costa C, Caproni S, Pisani A, Bonsi P, **Picconi B**, Cupini LM, Materazzi S, Geppetti P, Sarchielli P, Calabresi P (2012) Critical role of calcitonin gene-related peptide receptors in cortical spreading depression. Proc Natl Acad Sci U S A 109:18985-18990. **(IF = 9.68)**
4. Bagetta V, Sgobio C, Pendolino V, Del Papa G, Tozzi A, Ghiglieri V, Giampà C, Zianni E, Gardoni F, Calabresi P, **Picconi B** (2012) Rebalance of striatal NMDA-AMPA receptor ratio underlies the reduced emergence of dyskinesia during D2-like dopamine agonist treatment in experimental Parkinson's disease. JNeurosci. 32(49):17921-17931. **(IF = 7.12)**
5. Ghiglieri V, Bagetta V, Pendolino V, **Picconi B**, Calabresi P (2012) Corticostriatal Plastic Changes in Experimental L-DOPA-Induced Dyskinesia. Parkinsons Dis 2012:358176.
6. **Picconi B,** Calabresi P (2012) Rhes-mTORC1 interaction: a new possible therapeutic target in Parkinson's disease and L-dopa-induced dyskinesia? Mov Disord 27:815. **(IF = 4.505)**
7. Tozzi A, de Iure A, Marsili V, Romano R, Tantucci M, Di Filippo M, Costa C, Napolitano F, Mercuri NB, Borsini F, Giampa C, Fusco FR, **Picconi B**, Usiello A, Calabresi P (2012) A2A Adenosine Receptor Antagonism Enhances Synaptic and Motor Effects of Cocaine via CB1 Cannabinoid Receptor Activation. PLoS One 7:e38312. **(IF = 4.09)**
8. Costa C, Sgobio C, Siliquini S, Tozzi A, Tantucci M, Ghiglieri V, Di Filippo M, Pendolino V, de Iure A, Marti M, Morari M, Spillantini MG, Latagliata EC, Pascucci T, Puglisi-Allegra S, Gardoni F, Di Luca M, **Picconi B**, Calabresi P (2012) Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson's disease. Brain. 135(Pt 6):1884-99. **(IF = 9.23)**
9. Ghiglieri V, Pendolino V, Sgobio C, Bagetta V, **Picconi B**, Calabresi P (2012) Theta-burst stimulation and striatal plasticity in experimental parkinsonism. Exp Neurol 236:395-398. **(IF = 4.43)**
10. Ghiglieri V, Picconi B, Calabresi P (2012) Prenatal stress and hippocampal BDNF expression: a fading imperative. J Physiol 590:1309-1310. **(IF = 5.139)**
11. **Picconi B**, Piccoli G, Calabresi P (2012) Synaptic dysfunction in Parkinson's disease. (2012) Adv Exp Med Biol 970:553-572. **(IF = 1.379)**
12. Vastagh C, Gardoni F, Bagetta V, Stanic J, Zianni E, Giampa C, **Picconi B**, Calabresi P, Di Luca M (2012) N-Methyl-D-aspartate (NMDA) Receptor Composition Modulates Dendritic Spine Morphology in Striatal Medium Spiny Neurons. J Biol Chem 287:18103-18114. **(IF = 5.328)**
13. Gardoni F, Sgobio C, Pendolino V, Calabresi P, Di Luca M, **Picconi B**. (2012) Targeting NR2A-containing NMDA receptors reduces L-DOPA-induced dyskinesias. Neurobiol Aging. 33:2138–44 **(IF = 5.96)**
14. Ghiglieri V, Bagetta V, Calabresi P, **Picconi B**. (2012) Functional interactions within striatal microcircuit in animal models of huntington's disease. Neuroscience. 211:165-84 **(IF = 3.56)**

15. Tozzi A, Costa C, Siliquini S, Tantucci M, **Picconi B,** Kurz A, Gispert S, Auburger G, Calabresi P (2011) Mechanisms underlying altered striatal synaptic plasticity in old A53T-alpha synuclein overexpressing mice. Neurobiol Aging 33:1792-1799. **(IF = 5.96)**
16. Errico F, Bonito-Oliva A, Bagetta V, Vitucci D, Romano R, Zianni E, Napolitano F, Marinucci S, Di Luca M, Calabresi P, Fisone G, Carta M, **Picconi B**, Gardoni F, Usiello A (2011) Higher free d-aspartate and N-methyl-d-aspartate levels prevent striatal depotentiation and anticipate l-DOPA-induced dyskinesia. Exp Neurol. 232:240-50. **(IF = 3.97)**
17. Bagetta V, **Picconi B**, Marinucci S, Sgobio C, Pendolino V, Ghiglieri V, Fusco FR, Giampà C, Calabresi P (2011) Dopamine-dependent long-term depression is expressed in striatal spiny neurons of both direct and indirect pathways: implications for Parkinson's disease. J Neurosci. 31:12513-22 **(IF = 7.45)**
18. Ghiglieri V, Sgobio C, Costa C, **Picconi B**, Calabresi P. (2011) Striatum-hippocampus balance: from physiological behavior to interneuronal pathology. Prog Neurobiol. 94:102-14. **(IF = 9.13)**
19. Tozzi A, de Iure A, Di Filippo M, Tantucci M, Costa C, Borsini F, Ghiglieri V, Giampa C, Fusco FR, **Picconi B**, Calabresi P (2011) The distinct role of medium spiny neurons and cholinergic interneurons in the D2/A2A receptor interaction in the striatum: implications for Parkinson's disease. J Neurosci. 31:1850-62**.** **(IF = 7.45)**
20. **Picconi B**, Bagetta V, Ghiglieri V, Paille V, Di Filippo M, Pendolino V, Tozzi A, Giampa C, Fusco FR, Sgobio C, Calabresi P (2010) Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia. Brain. 134:375-87 **(IF = 9.6)**
21. Calabresi P, Filippo MD, Ghiglieri V, Tambasco N, **Picconi B**. (2010) Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap. Lancet Neurol 9:1106-1117. **(IF = 14.27)**
22. Ghiglieri V, Pendolino V, Bagetta V, Sgobio C, Calabresi P, **Picconi B**. (2010) mTOR inhibitor rapamycin suppresses striatal post-ischemic LTP. Exp Neurol 226:328-331. **(IF = 3.97)**
23. **Picconi B**, Ghiglieri V, Calabresi P. (2010) L-3,4-dihydroxyphenylalanine-induced sprouting of serotonin axon terminals: A useful biomarker for dyskinesias? Ann Neurol 68:578-580. **(IF = 9.93)**
24. Paillé V, **Picconi B**, Bagetta V, Ghiglieri V, Sgobio C, Di Filippo M, Viscomi MT, Giampà C, Fusco FR, Gardoni F, Bernardi G, Greengard P, Di Luca M, Calabresi P. (2010) Distinct levels of dopamine denervation differentially alter striatal synaptic plasticity and NMDA receptor subunit composition. J Neurosci 30:14182-14193. **(IF = 7.49)**
25. Ghiglieri V, **Picconi B**, Calabresi P (2010) Direct and indirect pathways in levodopa-induced dyskinesia: A more complex matter than a network imbalance. Mov Disord 25:1527-1529. **(IF = 3.89)**
26. Di Filippo M, Chiasserini D, Tozzi A, **Picconi B**, Calabresi P (2010) Mitochondria and the link between neuroinflammation and neurodegeneration. J Alzheimers Dis 20 Suppl 2:S369-379. **(IF = 5.1)**
27. Gubellini P, **Picconi B**, Di Filippo M, Calabresi P (2010) Downstream mechanisms triggered by mitochondrial dysfunction in the basal ganglia: From experimental models to neurodegenerative diseases. Biochim Biophys Acta 1802:151-161. **(IF = 2.64)**
28. Bagetta V, Ghiglieri V, Sgobio C, Calabresi P, **Picconi B** (2010) Synaptic dysfunction in Parkinson's disease. Biochem Soc Trans 38:493-497. **(IF = 2.97)**
29. Ghiglieri V, Sgobio C, Patassini S, Bagetta V, Fejtova A, Giampa C, Marinucci S, Heyden A, Gundelfinger ED, Fusco FR, Calabresi P, **Picconi B** (2010) TrkB/BDNF-Dependent Striatal Plasticity and Behavior in a Genetic Model of Epilepsy: Modulation by Valproic Acid. Neuropsychopharmacology 35:1531-1540. **(IF = 6.83)**
30. Sgobio C, Ghiglieri V, Costa C, Bagetta V, Siliquini S, Barone I, Di Filippo M, Gardoni F, Gundelfinger ED, Di Luca M, **Picconi B**, Calabresi P (2010) Hippocampal synaptic plasticity,

memory, and epilepsy: effects of long-term valproic acid treatment. Biol Psychiatry 67:567-574. **(IF = 8.67)**

31. Costa C, Tozzi A, Luchetti E, Siliquini S, Belcastro V, Tantucci M, **Picconi B**, Ientile R, Calabresi P, Pisani F (2010) Electrophysiological actions of zonisamide on striatal neurons: Selective neuroprotection against complex I mitochondrial dysfunction. Exp Neurol 221:217-224. **(IF = 3.97)**
32. Di Filippo M, Tozzi A, Ghiglieri V, **Picconi B**, Costa C, Cipriani S, Tantucci M, Belcastro V, Calabresi P (2009) Impaired Plasticity at Specific Subset of Striatal Synapses in the Ts65Dn Mouse Model of Down Syndrome. Biol Psychiatry 2010:67:666-671. **(IF = 8.67)**
33. Belcastro V, Tozzi A, Tantucci M, Costa C, Di Filippo M, Autuori A, **Picconi B**, Siliquini S, Luchetti E, Borsini F, Calabresi P (2009) A2A adenosine receptor antagonists protect the striatum against rotenone-induced neurotoxicity. Exp Neurol 217:231-234. **(IF = 3.97)**
34. Di Filippo M, **Picconi B**, Tantucci M, Ghiglieri V, Bagetta V, Sgobio C, Tozzi A, Parnetti L, Calabresi P (2009) Short-term and long-term plasticity at corticostriatal synapses: implications for learning and memory. Behav Brain Res 199:108-118. **(IF = 3.17)**
35. Ghiglieri V, **Picconi B**, Sgobio C, Bagetta V, Barone I, Paille V, Di Filippo M, Polli F, Gardoni F, Altrock W, Gundelfinger ED, De Sarro G, Bernardi G, Ammassari-Teule M, Di Luca M, Calabresi P (2009) Epilepsy-induced abnormal striatal plasticity in Bassoon mutant mice. Eur J Neurosci 29:1979-1993. **(IF = 3.38)**
36. Gardoni F, Mauceri D, Malinverno M, Polli F, Costa C, Tozzi A, Siliquini S, **Picconi B**, Cattabeni F, Calabresi P, Di Luca M (2009) Decreased NR2B subunit synaptic levels cause impaired long-term potentiation but not long-term depression. J Neurosci 29:669-677. **(IF = 7.49)**
37. Bagetta V, Barone I, Ghiglieri V, Di Filippo M, Sgobio C, Bernardi G, Calabresi P, **Picconi B** (2008) Acetyl-L-Carnitine selectively prevents post-ischemic LTP via a possible action on mitochondrial energy metabolism. Neuropharmacology 55:223-229. **(IF = 3.22)**
38. **Picconi B**, Paille V, Ghiglieri V, Bagetta V, Barone I, Lindgren HS, Bernardi G, Angela Cenci M, Calabresi P (2008) l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation. Neurobiol Dis 29:327-335. **(IF = 4.37)**
39. **Picconi B**, Ghiglieri V, Bagetta V, Barone I, Sgobio C, Calabresi P (2008) Striatal synaptic changes in experimental parkinsonism: role of NMDA receptor trafficking in PSD. Parkinsonism Relat Disord 14 Suppl 2:S145-149. **(IF = 2.02)**
40. Calabresi P, Di Filippo M, Ghiglieri V, **Picconi B** (2008) Molecular mechanisms underlying levodopa-induced dyskinesia. Mov Disord 23 Suppl 3:S570-579. **(IF = 3.89)**
41. Di Filippo M, Tozzi A, Costa C, Belcastro V, Tantucci M, **Picconi B**, Calabresi P (2008) Plasticity and repair in the post-ischemic brain. Neuropharmacology 55:353-362. **(IF = 3.22)**
42. Costa C, Belcastro V, Tozzi A, Di Filippo M, Tantucci M, Siliquini S, Autuori A, **Picconi B**, Spillantini MG, Fedele E, Pittaluga A, Raiteri M, Calabresi P (2008) Electrophysiology and pharmacology of striatal neuronal dysfunction induced by mitochondrial complex I inhibition. J Neurosci 28:8040-8052. **(IF = 7.45)**
43. Di Filippo M, Picconi B, Tozzi A, Ghiglieri V, Rossi A, Calabresi P (2008) The endocannabinoid system in Parkinson's disease. Curr Pharm Des 14:2337-2347. **(IF = 4.39)**
44. Di Filippo M, Sarchielli P, Picconi B, Calabresi P (2008) Neuroinflammation and synaptic plasticity: theoretical basis for a novel, immune-centred, therapeutic approach to neurological disorders. Trends Pharmacol Sci 29:402-412**.** **(IF = 9.34)**